POLIFARMATSIYA VA DORI–DORI O‘ZARO TA’SIRLARI: KLINIK XAVFLAR, PROFILAKTIKA VA DORI KO‘RIB CHIQISH (MEDICATION REVIEW) ALGORITMLARI
##semicolon##
polifarmatsiya##common.commaListSeparator## dori–dori o‘zaro ta’siri##common.commaListSeparator## nojo‘ya dori reaksiyasi##common.commaListSeparator## dori xavfsizligi##common.commaListSeparator## medication reconciliationAbstrak
Polifarmatsiya (odatda 5 va undan ortiq dori vositasini bir vaqtda qabul qilish) ko‘p kasallikli bemorlarda klinik natijalarni yaxshilashi mumkin, biroq u dori–dori o‘zaro ta’sirlari (DDI), nojo‘ya dori reaksiyalari, dori xatolari, adherens pasayishi hamda davolash xarajatlarining ortishi bilan bog‘liq xavflarni sezilarli oshiradi. Ayniqsa, keksa yosh, buyrak/jigar funksiyasi pasayishi, tor terapevtik oraliqli preparatlar (antikoagulyantlar, antiaritmiklar va boshqalar) qabul qilinishi hamda OTC/fitopreparatlar qo‘shilishi klinik ahamiyatli DDI ehtimolini kuchaytiradi. Ushbu tahliliy maqolada polifarmatsiyaning asosiy sabablari va “o‘rinli” hamda “muammoli” polifarmatsiya tushunchalari yoritiladi; farmakokinetik (CYP fermentlari, P-gp, absorbsiya va eliminatsiya o‘zgarishi) va farmakodinamik (qon ketish, giperkalemiya, sedatsiya/yiqilish, QT oralig‘i uzayishi) o‘zaro ta’sir mexanizmlari tizimlashtiriladi. Shuningdek, xavfni kamaytirish uchun dori yarashtirish (medication reconciliation), strukturali dori ko‘rib chiqish (medication review), skrining mezonlari (Beers, STOPP/START) hamda “Avoid–Adjust–Monitor” tamoyiliga asoslangan amaliy boshqaruv algoritmi taklif etiladi. Maqola yakunida individual depreskribing yondashuvi va monitoring orqali polifarmatsiya xavfsizligini oshirish bo‘yicha tavsiyalar beriladi
##submission.citations##
1. World Health Organization. Medication Safety in Polypharmacy: Technical Report. Geneva: World Health Organization, 2019. URL: https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019
2. NICE. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes: NICE guideline NG5. London: National Institute for Health and Care Excellence, 2015. URL: https://www.nice.org.uk/guidance/ng5/resources/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes-pdf-51041805253
3. Ayalew M. B., Tegegn H. G., Abdela O. A. Drug Related Hospital Admissions; A Systematic Review of the Recent Literatures // Bulletin of Emergency & Trauma. – 2019. Vol. 7, No. 4. P. 339–346.
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6911719/
4. O’Mahony D., Cherubini A., Renom-Guiteras A. et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3 // European Geriatric Medicine. 2023. Vol. 14, No. 4. P. 625–632. DOI: 10.1007/s41999-023-00777-y.
URL: https://pubmed.ncbi.nlm.nih.gov/37256475/
5. Davies L. E., Spiers G., Kingston A., Todd A., Adamson J., Hanratty B. Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews // Journal of the American Medical Directors Association (JAMDA). 2020. DOI: 10.1016/j.jamda.2019.10.022. URL: https://pubmed.ncbi.nlm.nih.gov/31926797/
6. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults // Journal of the American Geriatrics Society. 2023. DOI: 10.1111/jgs.18372.
URL: https://pubmed.ncbi.nlm.nih.gov/37139824/
7. O’Mahony D. et al. STOPP/START version 3: correction // European Geriatric Medicine. 2023. Vol. 14, No. 4. P. 633. DOI: 10.1007/s41999-023-00812-y.
URL: https://pubmed.ncbi.nlm.nih.gov/37256475/
8. Dautzenberg L. et al. Medication review interventions to reduce hospital readmissions in older people: systematic review and network meta-analysis // (PubMed). 2021. PMID: 33576506.
URL: https://pubmed.ncbi.nlm.nih.gov/33576506/
9. Bülow C. et al. Medication review in hospitalised patients to reduce morbidity and mortality // Cochrane Database of Systematic Reviews. 2023.
